The reiteration of an Equal-Weight rating and maintenance of a $22 price target by Stephens & Co. suggests a neutral outlook on RXO's stock in the short term. This indicates that the analyst sees the company as properly valued at its current price level, with no immediate catalysts expected to significantly change its valuation. Therefore, the impact on RXO's stock price is likely to be minimal in the short term, as the market has likely already priced in the analyst's expectations.